维奈克拉联合阿扎胞苷与地西他滨联合预激方案治疗老年急性髓系白血病的效果和安全性比较  

Comparison of efficacy and safety of venetoclax combined with azacytidine and decitabine combined with priming regimen in the treatment of elderly acute myeloid leukemia

作　　者：卜声镝 胡淑芳 李虹颖[1] 李善善 陆翔[1] BU Shengdi;HU Shufang;LI Hongying;LI Shanshan;LU Xiang(Department of Hematology,the First People’s Hospital of Nanning,Guangxi,Nanning 530000,China)

机构地区：[1]南宁市第一人民医院血液内科,广西南宁530000

出　　处：《中国医药科学》2023年第16期81-84,共4页China Medicine And Pharmacy

基　　金：广西壮族自治区卫生健康委员会自筹经费科研课题(Z20210662)。

摘　　要：目的 探讨维奈克拉联合阿扎胞苷与地西他滨联合预激方案治疗老年急性髓系白血病的疗效和安全性。方法 选取南宁市第一人民医院2019年2月至2022年2月收治的老年新诊断急性髓系白血病(AML)患者50例为研究对象,观察组采用维奈克拉联合阿扎胞苷治疗25例,对照组采用地西他滨联合预激方案治疗,比较两组患者总缓解率(ORR)率和不良反应发生率情况。结果 观察组患者ORR高于对照组,差异有统计学意义(P<0.05)。观察组患者白细胞减少、血小板减少、感染发生率均低于对照组,差异有统计学意义(P<0.05)两组30 d、60 d病死率、血红蛋白减少、低钾血症、腹泻、腹痛、发热、咳嗽发生率比较,差异无统计学意义(P>0.05)。结论 与地西他滨联合预激方案比较,维奈克拉联合阿扎胞苷治疗老年新诊断急性髓系白血病,总缓解率高,不良反应可控,值得进一步探索。Objective To investigate the efficacy and safety of venetoclax combined with azacytidine versus decitabine combined with priming regimen in the treatment of elderly acute myeloid leukemia.Methods A total of 50 elderly patients with newly diagnosed acute myeloid leukemia(AML)who were admitted to the First People’s Hospital of Nanning from February 2019 to February 2022 were selected as the study subjects.Twenty-five patients in the observation group were treated with venetoclax combined with azacytidine,while 25 patients in the control group were treated with decitabine combined with priming regimen.The overall response rate(ORR)and incidence of adverse reactions between the two groups were compared.Results The ORR of patients in the observation group was higher than that in the control group,with statistically significant difference(P<0.05).The incidences of leukopenia,thrombocytopenia,infection of observation group were lower than those in the control group,with statistically significant differences(P<0.05).The 30-day and 60-day mortalities,decreased hemoglobin,hypokalemia,diarrhea,abdominal pain,fever,cough of two group were comparied,the differences were no statistically significant(P>0.05).Conclusion Compared with decitabine combined with priming regimen,the treatment of venetoclax combined with azacytidine in the elderly with newly diagnosed acute myeloid leukemia has a high overall response rate and controllable adverse reactions.Therefore,it is worthy of further exploration.

关 键 词：维奈克拉 阿扎胞苷 地西他滨 预激方案 老年急性髓系白血病 

分 类 号：R733[医药卫生—肿瘤]